Skip to main content
. Author manuscript; available in PMC: 2015 Dec 18.
Published in final edited form as: Immunity. 2014 Nov 25;41(6):1052–1063. doi: 10.1016/j.immuni.2014.11.009

Figure 6. Combined treatment with anti-IL-17A and 5-FU results in a stronger therapeutic effect.

Figure 6

(A) CPC-APC mice were treated with 5-FU (50 mg/kg) for two consecutive days each week for 6 weeks. PBS was used as a control. Colonic tumors were analyzed by Q-RT-PCR for IL-17A and IL-17F mRNAs. (B, C) 3.5-month-old CPC-APC mice were treated with isotype control (Con), anti-IL-17A (Ab), 5-FU + isotype control (5-FU) or 5-FU + anti-IL-17A (Ab + 5-FU) for 6 weeks and sacrificed for analysis of tumor parameters (B, n=8) and Q-RT-PCR analysis of IL-6 mRNA (C, n=21). (D, E) 5-month-old CPC-APC mice were treated with isotype control (Con), anti-IL-17A (Ab), 5-FU + isotype control (5-FU) or 5-FU + anti-IL-17A (Ab + 5-FU) for 2 weeks and sacrificed. Colonic tumors were embedded in paraffin blocks and analyzed for Ki-67 (D) and cleaved caspase 3 (E). 8 HMF images were used for quantification in D and E. Data are averages ± S.E.M. * p < 0.05. * p < 0.05. Scale bar = 100 μm.